Skip to main content
L

Not yet reviewed: this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

Zolazepam

This article is a stubmissing:
Subjective Effects
Interactions
Tolerance
Legality
Zolazepam molecule structureZolazepam molecule structure
Open in Piru

Zolazepam is a depressant1 and pyrazolodiazepinone derivative structurally related to benzodiazepines.2 It is used as an anaesthetic in veterinary medicine,3 usually in combination with tiletamine or xylazine.3 It was developed by Horace A. de Wald and Donald E. Butler for Parke-Davis. Zolazepam is described as more potent than diazepam and reportedly soluble in water.3 It is classified as habit-forming.

Dosage & Duration

Log in Piru

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~1 mg
Light1-3 mg
Moderate3-6 mg
Strong6-12 mg
Heavy12+ mg

Subjective Effects

Subjective Effects not written up yet

Pharmacology

Pharmacodynamics

Zolazepam is a pyrazolodiazepinone derivative that is structurally related to the benzodiazepines and produces anaesthetic and depressant effects in veterinary use. Reported potency relative to diazepam varies across sources, with estimates ranging from roughly four times to five to ten times that of diazepam. It is typically given alongside other agents, such as the NMDA antagonist tiletamine or the α2 adrenergic receptor agonist xylazine, depending on the intended purpose.

Pharmacokinetics

Absorption & half-lifenot documented yetMetabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance not written up yet

Harm Potential

Addiction & Dependence

Psychological

Zolazepam has habit-forming potential.

History & Culture

Zolazepam, also known as flupyrazapon, was developed by Horace A. de Wald and Donald E. Butler for Parke-Davis, emerging from a detailed structural analysis of the benzodiazepine class. The resulting compound, a pyrazolodiazepinone derivative, was covered by U.S. patent 3,558,605, filed in 1969.…

Legality

Legality not written up yet

References

Citations

  1. Controlled Drug Schedules, Violations & Penalties. Connecticut Department of Consumer Protection (2026). https://portal.ct.gov/dcp/-/media/dcp/drug_control/pdf/controlleddrugschedulesviolationspenaltiespdf.pdf?hash=F848DC7DBA3B4523BB82EDC751190EA0&rev=074e7ec752a744f790b01def90e9baaa1
  2. Zolazepam hydrochloride solution. Sigma-Aldrich / Cerilliant (n.d.). https://www.sigmaaldrich.com/US/en/product/cerillian/z0201
  3. Zolazepam: Uses, Interactions, Mechanism of Action. DrugBank (n.d.). https://go.drugbank.com/drugs/DB11555123

Further Reading

  1. de la Peña & Cheong 2016 - The abuse liability of the NMDA receptor antagonist‐benzodiazepine (tiletamine‐zolazepam) combination: evidence from clinical case reports and preclinical studies

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed: this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the Zolazepam article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.